Insights into Schizophrenia from Research with Clozapine and Other Atypical Antipsychotics
18 January 2017 12:00 to 13:00 EST
220 Mass. Avenue, Cambridge MA - USA
Speaker: Herbert Y Meltzer, MD Professor of Psychiatry and Behavioral Sciences, Pharmacology and Physiology Northwestern University, Feinberg School of Medicine
Seminar Abstract: This seminar will consider my current approaches to advancing the treatment for schizophrenia and related psychoses, which developed from translational research with clozapine, related atypical antipsychotic drugs, and pimavanserin, a selective 5-HT2A inverse agonist, and the first approved non-dopamine targeting APD to treat psychosis. I will present data on the ability of atypical APDs as a class to improve cognitive impairment associated with schizophrenia, new and published pharmacogenetic study data pointing towards synaptic targets as the principal site of action of atypical APDs for psychopathology in general, and preclinical behavioral and microdialysis studies of rodent models of cognitive impairment, psychosis and social interaction deficits, which suggest new drug targets.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Herbert Y Meltzer
Speaker | Herbert Y Meltzer, MD
Dr Meltzer received a BA from Cornell University, an MA in Chemistry from Harvard, and an MD from Yale University, trained in Psychiatry and Research at the Mass Mental Health Center and NIMH, where he was mentored by Eric Kandel and members of the Seymour Kety lab, respectively. He has conducted basic and clinical research on psychotropic drugs since 1964.. Dr Meltzer has an extensive history as an advisor to Sandoz/Novartis and numerous other pharmaceutical companies in the development of psychotropic drugs. He has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). Dr. Meltzer has received numerous awards for his research from the ACNP, the Lieber Prize for Schizophrenia Research from NARSAD, the Society of Biological Psychiatry, Vanderbilt University, the American Psychiatric Association, the Lifetime Achievement Award of the Schizophrenia International Research Society (2016), and the Pioneer Award from the CINP (2016). Dr Meltzer is particularly interested in the cognitive impairment associated with schizophrenia and other neuropsychiatric disorders and the mechanisms underlying the heterogeneity of its response to drugs in patients and animal models. His Hirsch index is 121.